/EINPresswire.com/ -- TORONTO, ON--(Marketwired - January 20, 2017) - Join Vincent Legay, Consulting Services Manager at NAMSA, for an informative session on Wednesday, February 8, 2017 at 10am EST (3pm GMT).

A clinical evaluation is the assessment and analysis of clinical data needed to verify the clinical safety and performance of your medical device. A Clinical Evaluation Report (CER) outlines the scope and context of the clinical evaluation of your device and includes the actual clinical data, the appraisal and analysis stages of the evaluation, and conclusions about device safety and performance.

The collection of clinical data is a critical aspect in the conformity assessment process of medical devices, and serves to substantiate a manufacturer's claim regarding the safety, performance and benefit/risk ratio of a given device. Clinical data is generally understood as evidence on the safety and performance of a medical device based on actual usage of the device, and is typically derived from pre-clinical or clinical investigations, scientific literature and/or clinical experiences with similar devices.

Clinical evaluation reports should be considered live documents and should remain active throughout the lifetime of the device with regular reviews and updates in relation to the results of post market surveillance activities and as and when more clinical data becomes available. This emphasises the importance of building the Clinical Evaluation report on solid foundations in order to facilitate subsequent revisions and incorporate relevant data.

Originally, the Clinical Evaluation Report, formed a significant part of a Technical File or Design Dossier. Following proposals for EU Regulation (EU MDR), as well as MEDDEV 2.7/1 revision 4 (June 2016), the Clinical Evaluation Report should now be looked as a standalone document summarizing any kind of data/evidence on the device under evaluation, in alignment with the intended claims, residual risks, benefits and risks as summarized into the Technical file or design dossier. The Clinical Evaluation Report should also be verifying these data do support any information and materials (Instruction for Use, Marketing brochures…) where device's claim is being made to ensure it is accurately evidenced by data The Clinical Evaluation Report should also be thoroughly prepared with regards to any therapeutic alternatives, surgical practices, similar devices, in order to establish a solid State Of The Art, pre-requisite to any device development to address a clinical need. Completion of a Clinical Evaluation Report when first conducting the conformity assessment (CE Mark) process can help Manufacturers understand whether a clinical investigation is necessary, or required, or identify any alternative way of gathering evidence supporting a claim or addressing a risk (further pre-clinical tests, deeper risk analysis, re-design, etc.

In the post market phase continued evaluation of the device is essential for identifying further risks that occur with use of the device and, if necessary, may result in changes to the Instruction for Use and product labelling.

The European Commission Guidance MEDDEV 2.7/1 rev. 4 Clinical Evaluation: Guide for Manufacturers and Notified Bodies provides details on the process of conducting clinical evaluations and the requirements for creating a Clinical Evaluation Report. The document also provides a list of references that can be useful.

For more information or to register for this free event visit: Clinical Evaluation Reports: Global Benefits and What the new MEDDEV Updates Means To Manufacturers

About NAMSA:

NAMSA is a Medical Research Organization (MRO), accelerating product development through integrated laboratory, clinical and consulting services. Driven by our regulatory expertise, NAMSA's MRO® Approach plays an important role in translational research, applying a unique combination of disciplines-consulting, preclinical, toxicology, microbiology, chemistry, clinical and quality-to move client's products through the development process, and continue to provide support through commercialization to post-market requirements, anywhere in the world.

To learn more about NAMSA visit www.namsa.com

Or contact clientcare@namsa.com

About Xtalks:

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2017/1/18/11G127795/Images/NAMSA_Logo_(2014)_-_Web_Colors_-_RGB-bf17035d19c9bfb0868562437108f1ba.JPG